This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pacific Biosciences of California (PACB) Stock Moves -1.18%: What You Should Know
by Zacks Equity Research
Pacific Biosciences of California (PACB) closed at $1.67 in the latest trading session, marking a -1.18% move from the prior day.
Here's Why You Should Retain PacBio Stock in Your Portfolio for Now
by Zacks Equity Research
PACB continues to deliver growth from its unique technologies amid business seasonality concerns.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
PACB Stock Declines Despite Promising HiFi Sequencing Findings
by Zacks Equity Research
PacBio announces positive study results for HiFi long-read sequencing technology in identifying genetic causes of rare diseases.
PACB Stock Falls on Preliminary Q4 Sales Miss, 7 Vega Systems Shipped
by Zacks Equity Research
PacBio reports dismal preliminary fourth-quarter 2024 results, caused by lower instrument. New launches and clinical focus set the stage for market growth in 2025.
PacBio Stock May Gain Following the Collaborated Launch of GutID
by Zacks Equity Research
PACB and Intus Bio collaborate to launch GutID, the first commercial human gut health test.
PACB Stock Rises After the Shipment of Vega Systems to Berry Genomics
by Zacks Equity Research
PacBio delivers the first Vega systems to Berry Genomics to develop and optimize its targeted assays to support screening programs in China and other markets.
Why the Market Dipped But Pacific Biosciences of California (PACB) Gained Today
by Zacks Equity Research
Pacific Biosciences of California (PACB) closed at $2 in the latest trading session, marking a +0.5% move from the prior day.
Reasons to Retain PacBio Stock in Your Portfolio for Now
by Zacks Equity Research
PACB continues to deliver growth from its unique technologies amid business seasonality concerns.
PACB Stock Falls Despite Q3 Earnings Beat, Revenues Decline Y/Y
by Zacks Equity Research
PacBio Q3 2024 revenues decline year over year. However, Consumable, and Service and other revenues increase.
Pacific Biosciences (PACB) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Pacific Biosciences (PACB) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Pacific Biosciences of California (PACB) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Pacific Biosciences (PACB) delivered earnings and revenue surprises of 15% and 4.60%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Curious about Pacific Biosciences (PACB) Q3 Performance? Explore Wall Street Estimates for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Pacific Biosciences (PACB) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Pacific Biosciences of California (PACB) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
Pacific Biosciences of California (PACB) reachead $2.17 at the closing of the latest trading day, reflecting a +0.46% change compared to its last close.
Alphatec (ATEC) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alphatec (ATEC) delivered earnings and revenue surprises of -3.70% and 2.19%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Illumina's Q3 Earnings Coming Up: Time to Buy, Sell or Hold the Stock?
by Moumi Mondal
In the third quarter of 2024, ILMN is likely to have benefited from the significant step-up in consumables with growing customer activity on NovaSeq X.
ILMN Stock Trading Near 52-Week High: Should You Buy, Sell or Hold?
by Moumi Mondal
Reaching a new one-year high, Illumina remains in investors' sight owing to its strong strategic execution and positive growth outlook.
Pacific Biosciences of California (PACB) Stock Slides as Market Rises: Facts to Know Before You Trade
by Zacks Equity Research
In the latest trading session, Pacific Biosciences of California (PACB) closed at $2.06, marking a -1.9% move from the previous day.
Reasons to Retain PacBio Stock in Your Portfolio for Now
by Zacks Equity Research
PACB's strong product demand and continued focus on R&D raise optimism about the stock.
PacBio Shares Rise After NCCS Partnership for Cancer Genomics Research
by Zacks Equity Research
PACB partners with NCCS to enhance cancer research using the Onso short-read platform and Revio long-read sequencing, advancing precision oncology in Singapore and Asia.
OPK Gets Additional BARDA Funding to Develop Multispecific Antibodies
by Zacks Equity Research
OPKO Health's receipt of the additional funding from BARDA is expected to explore the MSTAR platform to prepare for outbreaks and respond rapidly to emerging viral threats.
Pacific Biosciences of California (PACB) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
Pacific Biosciences of California (PACB) closed at $1.75 in the latest trading session, marking a +0.57% move from the prior day.
Pacific Biosciences of California (PACB) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
Pacific Biosciences of California (PACB) closed at $1.81 in the latest trading session, marking a +0.56% move from the prior day.
PacBio Stock Drops After Singapore Collaboration for HiFi Sequencing
by Zacks Equity Research
PACB's HiFi sequencing powers the HiFi Consortium's global effort to enhance the diagnosis and treatment of subfertility and recurrent pregnancy loss.